期刊
JOURNAL OF PATHOLOGY
卷 236, 期 4, 页码 517-530出版社
WILEY
DOI: 10.1002/path.4547
关键词
prostate cancer; cell metabolism; monocarboxylate transporters; poor prognosis markers; metabolic targets
资金
- Portuguese Foundation for Science and Technology (FCT) [SFRH/BD/61027/2009, PTDC/SAU-MET/113415/2009]
- Sao Paulo Research Foundation (FAPESP) [2013/08830-2, 2013/06802-1]
- Academy of Medical Sciences (AMS) [AMS-SGCL2-Tran] Funding Source: researchfish
- Fundação para a Ciência e a Tecnologia [PTDC/SAU-MET/113415/2009] Funding Source: FCT
Metabolic adaptation is considered an emerging hallmark of cancer, whereby cancer cells exhibit high rates of glucose consumption with consequent lactate production. To ensure rapid efflux of lactate, most cancer cells express high levels of monocarboxylate transporters (MCTs), which therefore may constitute suitable therapeutic targets. The impact of MCT inhibition, along with the clinical impact of altered cellular metabolism during prostate cancer (PCa) initiation and progression, has not been described. Using a large cohort of human prostate tissues of different grades, in silico data, in vitro and ex vivo studies, we demonstrate the metabolic heterogeneity of PCa and its clinical relevance. We show an increased glycolytic phenotype in advanced stages of PCa and its correlation with poor prognosis. Finally, we present evidence supporting MCTs as suitable targets in PCa, affecting not only cancer cell proliferation and survival but also the expression of a number of hypoxia-inducible factor target genes associated with poor prognosis. Herein, we suggest that patients with highly glycolytic tumours have poorer outcome, supporting the notion of targeting glycolytic tumour cells in prostate cancer through the use of MCT inhibitors. (c) 2015 Authors. Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据